William A Weiss

List of Publications by Year in Descending Order

140 papers	17,320 citations	59 h-index	131 g-index
146 ext. papers	19,654 ext. citations	13.2 avg, IF	6.02 L-index

#	Paper	IF	Citations
140	Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.. *Nature Medicine*, **2022**,	50.5	6
139	Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers. *Cancer Research*, **2021**, 81, 1627-1632	10.1	7
138	Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR Phosphorylation. *Molecular Cancer Therapeutics*, **2020**, 19, 1328-1339	6.1	6
137	Utility of Human-Derived Models for Glioblastoma. *Cancer Discovery*, **2020**, 10, 907-909	24.4	4
136	Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma. *Clinical Cancer Research*, **2020**, 26, 2457-2460	12.9	5
135	Betacellulin drives therapy resistance in glioblastoma. *Neuro-Oncology*, **2020**, 22, 457-469	1	2
134	Conversations on mutism: risk stratification for cerebellar mutism based on medulloblastoma subtype. *Neuro-Oncology*, **2020**, 22, 175-176	1	
133	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. *Cell Stem Cell*, **2019**, 25, 433-446.e7	18	31
132	Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. *Molecular Cancer Therapeutics*, **2019**, 18, 1565-1576	6.1	6
131	Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints. *Blood*, **2019**, 133, 1119-1129	2.2	45
130	A CK1Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. *Clinical Cancer Research*, **2019**, 25, 1379-1388	12.9	14
129	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. *Oncogene*, **2018** , 37, 2850-2862	9.2	38
128	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-OTX2-SNAIL via PTEN inhibition. *Brain*, **2018**, 141, 1300-1319	11.2	13
127	Antisecretory Factor-Mediated Inhibition of Cell Volume Dynamics Produces Antitumor Activity in Glioblastoma. *Molecular Cancer Research*, **2018**, 16, 777-790	6.6	10
126	Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. *Oncogene*, **2018**, 37, 1561-1575	9.2	210
125	Inhibiting 4EBP1 in Glioblastoma. *Clinical Cancer Research*, **2018**, 24, 14-21	12.9	16
124	An oncolytic measles virus-sensitive Group 3 medulloblastoma model in immune-competent mice. *Neuro-Oncology*, **2018**, 20, 1606-1615	1	10

123	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. *Journal of Clinical Investigation*, **2018**, 128, 446-462	15.9	72
122	Pediatric low-grade gliomas: next biologically driven steps. *Neuro-Oncology*, **2018**, 20, 160-173	1	76
121	EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. *Cancer Research*, **2018**, 78, 6785-6794	10.1	24
120	Dual HDAC and PI3K Inhibition Abrogates NFB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. *Cancer Research*, **2018**, 78, 4007-4021	10.1	36
119	A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. *Cancer Cell*, **2017**, 31, 424-435	24.3	90
118	Cross-activating c-Met/ integrin complex drives metastasis and invasive resistance in cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E8685-E8694	11.5	42
117	Neuroblastoma Metastases: Leveraging the Avian Neural Crest. *Cancer Cell*, **2017**, 32, 395-397	24.3	2
116	Pediatric high-grade glioma: biologically and clinically in need of new thinking. *Neuro-Oncology*, **2017**, 19, 153-161	1	125
115	Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma. *Oncogene*, **2017**, 36, 6306-6314	9.2	13
114	Glioblastoma cellular cross-talk converges on NF-B to attenuate EGFR inhibitor sensitivity. *Genes and Development*, **2017**, 31, 1212-1227	12.6	38
113	Combined BRAF and MEK blockade for BRAF-mutant gliomas. *Journal of Neuro-Oncology*, **2017**, 131, 495-505	4.8	24
112	Acquired resistance to BRAF inhibition in BRAFV600E mutant gliomas. *Oncotarget*, **2017**, 8, 583-595	3.3	16
111	Cholesterol: An AchillesSHeel for Glioblastoma?. *Cancer Cell*, **2016**, 30, 653-654	24.3	9
110	Divergent clonal selection dominates medulloblastoma at recurrence. *Nature*, **2016**, 529, 351-7	50.4	206
109	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. *Journal of Neuro-Oncology*, **2016**, 126, 385-93	4.8	25
108	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. *Lancet Oncology, The*, **2016**, 17, 484-495	21.7	187
107	Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. *Oncotarget*, **2016**, 7, 57525-57544	3.3	32
106	IKK/NF-B signaling contributes to glioblastoma stem cell maintenance. *Oncotarget*, **2016**, 7, 69173-69187	3.3	31

105	Rational design of a monomeric and photostable far-red fluorescent protein for fluorescence imaging in vivo. *Protein Science*, **2016**, 25, 308-15	6.3	22
104	BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas. *Clinical Cancer Research*, **2016**, 22, 5312-5321	12.9	35
103	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. *Clinical Cancer Research*, **2015**, 21, 3750-8	12.9	35
102	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. *Nature Neuroscience*, **2015**, 18, 1236-46	25.5	56
101	STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma. *Cancer Research*, **2015**, 75, 4302-11	10.1	58
100	Alternative splicing in cancer: implications for biology and therapy. *Oncogene*, **2015**, 34, 1-14	9.2	194
99	Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. *Frontiers in Oncology*, **2015**, 5, 111	5.3	16
98	Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma. *Molecular Cancer Therapeutics*, **2015**, 14, 419-28	6.1	20
97	A new "angle" on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition. *Molecular and Cellular Oncology*, **2015**, 2, e975641	1.2	2
96	The genetics of splicing in neuroblastoma. *Cancer Discovery*, **2015**, 5, 380-95	24.4	13
95	Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. *Cancer Cell*, **2015**, 27, 72-84	24.3	122
94	EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. *Oncotarget*, **2015**, 6, 21993-22005	3.3	19
93	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. *Nature*, **2014**, 506, 445-50	50.4	434
92	The prenatal origins of cancer. *Nature Reviews Cancer*, **2014**, 14, 277-89	31.3	153
91	BET bromodomain inhibition of MYC-amplified medulloblastoma. *Clinical Cancer Research*, **2014**, 20, 912-25	12.9	227
90	Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. *Science*, **2014**, 343, 189-193	33.3	912
89	When deletions gain functions: commandeering epigenetic mechanisms. *Cancer Cell*, **2014**, 26, 160-1	24.3	5
88	Cytogenetic prognostication within medulloblastoma subgroups. *Journal of Clinical Oncology*, **2014**, 32, 886-96	2.2	199

87	Drugging MYCN through an allosteric transition in Aurora kinase A. *Cancer Cell*, **2014**, 26, 414-427	24.3	179
86	Glial progenitors as targets for transformation in glioma. *Advances in Cancer Research*, **2014**, 121, 1-65	5.9	26
85	Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. *Cell Reports*, **2014**, 9, 1034-46	10.6	14
84	Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. *International Journal of Cancer*, **2014**, 134, 2437-47	7.5	73
83	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. *Acta Neuropathologica*, **2013**, 125, 373-84	14.3	126
82	Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E1480-9	11.5	24
81	EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. *Cancer Cell*, **2013**, 24, 438-49	24.3	181
80	Starvation favors glioma stem cells. *Nature Neuroscience*, **2013**, 16, 1359-61	25.5	4
79	Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. *Cancer Research*, **2013**, 73, 4086-97	10.1	44
78	What underlies the diversity of brain tumors?. *Cancer and Metastasis Reviews*, **2013**, 32, 5-24	9.6	15
77	Recapitulating human cancer in a mouse. *Nature Biotechnology*, **2013**, 31, 392-5	44.5	5
76	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathologica*, **2013**, 126, 917-29	14.3	115
75	Blockade of glioma proliferation through allosteric inhibition of JAK2. *Science Signaling*, **2013**, 6, ra55	8.8	20
74	G34, another connection between MYCN and a pediatric tumor. *Cancer Discovery*, **2013**, 3, 484-6	24.4	5
73	It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma. *Clinical Cancer Research*, **2013**, 19, 5811-3	12.9	13
72	Neuroblastoma and MYCN. *Cold Spring Harbor Perspectives in Medicine*, **2013**, 3, a014415	5.4	335
71	Targeting MYCN in neuroblastoma by BET bromodomain inhibition. *Cancer Discovery*, **2013**, 3, 308-23	24.4	460
70	Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. *Journal of Clinical Oncology*, **2013**, 31, 2927-35	2.2	290

69	Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. *Epigenetics*, **2013**, 8, 1254-60	5.7	14
68	Imaging-based chemical screening reveals activity-dependent neural differentiation of pluripotent stem cells. *ELife*, **2013**, 2, e00508	8.9	12
67	Matching mice to malignancy: molecular subgroups and models of medulloblastoma. *Childs Nervous System*, **2012**, 28, 521-32	1.7	18
66	Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 12722-7	11.5	30
65	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	10.2	2783
64	High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery. *Cancer Investigation*, **2012**, 30, 343-63	2.1	8
63	Clonal selection drives genetic divergence of metastatic medulloblastoma. *Nature*, **2012**, 482, 529-33	50.4	322
62	Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 8710-5	11.5	64
61	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 515-27	14.3	57
60	Subgroup-specific alternative splicing in medulloblastoma. *Acta Neuropathologica*, **2012**, 123, 485-499	14.3	23
59	Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. *Cancer Cell*, **2012**, 21, 601-613	24.3	141
58	Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. *Cancer Discovery*, **2012**, 2, 450-7	24.4	44
57	Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. *Science Translational Medicine*, **2012**, 4, 115ra3	17.5	66
56	PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. *Neuro-Oncology*, **2012**, 14, 1146-52	1	69
55	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. *Genes and Development*, **2012**, 26, 1780-96	12.6	54
54	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. *Nature*, **2012**, 488, 49-56	50.4	596
53	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. *Cancer Letters*, **2011**, 306, 223-9	9.9	54
52	Principles and current strategies for targeting autophagy for cancer treatment. *Clinical Cancer Research*, **2011**, 17, 654-66	12.9	687

51	Genetically engineered murine models--contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. *Seminars in Cancer Biology*, **2011**, 21, 245-55	12.7	39
50	Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. *Cancer Cell*, **2011**, 20, 143-57	24.3	395
49	Asymmetry-defective oligodendrocyte progenitors are glioma precursors. *Cancer Cell*, **2011**, 20, 328-40	24.3	168
48	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. *Childs Nervous System*, **2011**, 27, 1243-9	1.7	18
47	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. *Acta Neuropathologica*, **2011**, 122, 231-40	14.3	159
46	Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. *Clinical Cancer Research*, **2011**, 17, 2339-49	12.9	50
45	Targeted therapy for BRAFV600E malignant astrocytoma. *Clinical Cancer Research*, **2011**, 17, 7595-604	12.9	128
44	Autophagy and Akt promote survival in glioma. *Autophagy*, **2011**, 7, 536-8	10.2	45
43	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. *Neuro-Oncology*, **2011**, 13, 384-92	1	118
42	Myc proteins as therapeutic targets. *Oncogene*, **2010**, 29, 1249-59	9.2	151
41	miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. *Nature Medicine*, **2010**, 16, 1134-40	50.5	156
40	Intratumoral therapy of glioblastoma multiforme using genetically engineered transferrin for drug delivery. *Cancer Research*, **2010**, 70, 4520-7	10.1	35
39	Pleiotropic role for MYCN in medulloblastoma. *Genes and Development*, **2010**, 24, 1059-72	12.6	128
38	Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. *Medical Physics*, **2010**, 37, 4861-7	4.4	52
37	Akt and autophagy cooperate to promote survival of drug-resistant glioma. *Science Signaling*, **2010**, 3, ra81	8.8	225
36	Non-stem cell origin for oligodendroglioma. *Cancer Cell*, **2010**, 18, 669-82	24.3	183
35	A translational end-run for a rare, genetically enigmatic tumor. *Cancer Biology and Therapy*, **2009**, 8, 2396-7	4.6	
34	Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. *Cancer Research*, **2009**, 69, 8429-37	10.1	66

33	Adenovirus-mediated hPNPase(old-35) gene transfer as a therapeutic strategy for neuroblastoma. *Journal of Cellular Physiology*, **2009**, 219, 707-15	7	13
32	Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. *Oncogene*, **2009**, 28, 3121-31	9.2	74
31	PI3K signaling in glioma--animal models and therapeutic challenges. *Brain Pathology*, **2009**, 19, 112-20	6	93
30	The side story of stem-like glioma cells. *Cell Stem Cell*, **2009**, 4, 191-2	18	8
29	EGFR signals to mTOR through PKC and independently of Akt in glioma. *Science Signaling*, **2009**, 2, ra4	8.8	140
28	Involvement of RhoA, ROCK I and myosin II in inverted orientation of epithelial polarity. *EMBO Reports*, **2008**, 9, 923-9	6.5	95
27	Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. *Neoplasia*, **2008**, 10, 1268-74	6.4	52
26	Characterization of structurally distinct, isoform-selective phosphoinositide 3Skinase inhibitors in combination with radiation in the treatment of glioblastoma. *Molecular Cancer Therapeutics*, **2008**, 7, 841-50	6.1	54
25	BMPs oppose Math1 in cerebellar development and in medulloblastoma. *Genes and Development*, **2008**, 22, 693-9	12.6	22
24	Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. *Journal of Cellular Biochemistry*, **2007**, 102, 1529-41	4.7	27
23	Recognizing and exploiting differences between RNAi and small-molecule inhibitors. *Nature Chemical Biology*, **2007**, 3, 739-44	11.7	211
22	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. *Nature Chemical Biology*, **2007**, 3, 229-38	11.7	168
21	Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. *Cancer Research*, **2007**, 67, 9435-42	10.1	55
20	A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. *Cancer Research*, **2007**, 67, 7960-5	10.1	185
19	A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. *Cancer Cell*, **2006**, 9, 341-9	24.3	532
18	Isoform specific inhibitors of PI3 kinase in glioma. *Cell Cycle*, **2006**, 5, 2301-5	4.7	28
17	Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. *Cancer Research*, **2006**, 66, 8139-46	10.1	164
16	A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. *Cell*, **2006**, 125, 733-47	56.2	963

15	Chemical genetic approaches to the development of cancer therapeutics. *Current Opinion in Genetics and Development*, **2006**, 16, 85-91	4.9	3
14	Brain tumors in S100beta-v-erbB transgenic rats. *Journal of Neuropathology and Experimental Neurology*, **2006**, 65, 1111-7	3.1	13
13	Childhood tumors of the nervous system as disorders of normal development. *Current Opinion in Pediatrics*, **2006**, 18, 634-8	3.2	77
12	Epigenome analyses using BAC microarrays identify evolutionary conservation of tissue-specific methylation of SHANK3. *Nature Genetics*, **2005**, 37, 645-51	36.3	143
11	RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. *Oncogene*, **2005** , 24, 829-37	9.2	38
10	Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. *Cancer Research*, **2005**, 65, 3617-23	10.1	59
9	Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 12664-9	11.5	118
8	Can mouse models for brain tumors inform treatment in pediatric patients?. *Seminars in Cancer Biology*, **2004**, 14, 71-7	12.7	1
7	Neural stem cell biology may be well suited for improving brain tumor therapies. *Cancer Journal (Sudbury, Mass)*, **2003**, 9, 189-204	2.2	51
6	Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma. *Journal of the National Cancer Institute*, **2003**, 95, 1394-403	9.7	86
5	Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. *Current Biology*, **2002**, 12, 1386-94	6.3	27
4	A head holder for magnetic resonance imaging that allows the stereotaxic alignment of spontaneously occurring intracranial mouse tumors. *Journal of Neuroscience Methods*, **2002**, 116, 1-7	3	10
3	Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. *Oncogene*, **2002**, 21, 7453-63	9.2	59
2	Genetics of brain tumors. *Current Opinion in Pediatrics*, **2000**, 12, 543-8	3.2	16
1	Targeted expression of MYCN causes neuroblastoma in transgenic mice. *EMBO Journal*, **1997**, 16, 2985-95	13	573